Innovator Medicines Versus Generic Medicine Package Inserts Safety Amendments, the Reality in South Africa

Simple item page
dc.contributor.advisorO'Donoghue, Miriam
dc.contributor.advisorEagles, Peter
dc.contributor.authorMabunda, Hitekani Tolerance
dc.date.accessioned2018-08-16T13:10:26Z
dc.date.accessioned2024-10-29T14:20:10Z
dc.date.available2018-08-16T13:10:26Z
dc.date.available2024-10-29T14:20:10Z
dc.date.issued2017
dc.descriptionMagister Scientiae - MSc (Pharmacy Administration and Policy Regulation)
dc.description.abstractAvailability of clinically relevant and unbiased medicine information goes a long way in promoting rational use of medicines. The package insert (PI) is one of the sources of information utilised by healthcare professionals for accessing relevant medicine information such as indications, contra-indications and special precautions (Singh, Mohan, Kumar, & Gupta,2016). It is important that the PI contains updated safety information. The safety information in the PIs of the innovator and generic medicines are expected to be the similar since they contain the same active ingredients. Generic medicines have the same efficacy and safety as innovator medicines and are considered bioequivalent. Generic medicines are interchangeable with innovator medicines.
dc.identifier.urihttps://hdl.handle.net/10566/16362
dc.language.isoen
dc.publisherUniversity of the Western Cape
dc.rights.holderUniversity of the Western Cape
dc.titleInnovator Medicines Versus Generic Medicine Package Inserts Safety Amendments, the Reality in South Africa

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mabunda_MSC_NSC_2017.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format
Download

Collections

Magister Scientiae - MSc (Pharmacy Administration and Policy Regulation)